Annika Eklundh

Dr. Annika Eklundh

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 April 2021 in Vaccines
Verified
Journal Article
Open access
PDF file
AEAnnika Eklundh
Annika Eklundh
SRSamuel Arthur Rhedin
Samuel Arthur Rhedin
MRMalin Ryd Rinder
Malin Ryd Rinder
MAMaria Andersson
Maria Andersson
JGJesper Gantelius
Jesper Gantelius
TATobias Alfven
Tobias Alfven
(1) Immunization with pneumococcal conjugate vaccines has decreased the burden of community-acquired pneumonia (CAP) in children and likely led to a shift in CAP etiology. (2) The Trial of Respiratory infections in children for ENhanced Diagnostics (TREND) enrolled children 1-59 months with clinical CAP according to the World Health Organization (WHO) criteria at Sachs’ Children and Youth Hospital, Stockholm, Sweden. Children with rhonchi and indrawing underwent “bronchodilator challenge”. C-reactive protein and nasopharyngeal PCR detecting 20 respiratory pathogens, were collected from all children. Etiology was defined according to an a priori defined algorithm based on microbiological, biochemical, and radiological findings. (3) Of 327 enrolled children, 107 (32%) required hospitalization; 91 (28%) received antibiotic treatment; 77 (24%) had a chest X-ray performed; and 60 (18%) responded to bronchodilator challenge. 243 (74%) episodes were classified as viral, 11 (3%) as mixed viral-bacterial, five (2%) as bacterial, two (0.6%) as atypical bacterial and 66 (20%) as undetermined etiology. After exclusion of children responding to bronchodilator challenge, the proportion of bacterial and mixed viral-bacterial etiology was 1% and 4%, respectively. (4) The novel TREND etiology algorithm classified the majority of clinical CAP episodes as of viral etiology, whereas bacterial etiology was uncommon. Defining CAP in children <5 years is challenging, and the WHO definition of clinical CAP is not suitable for use in children immunized with pneumococcal conjugate vaccines.

26 April 2019 in JMIR Research Protocols
Verified
Journal Article
Open access
SRSamuel Arthur Rhedin
Samuel Arthur Rhedin
AEAnnika Eklundh
Annika Eklundh
MRMalin Ryd Rinder
Malin Ryd Rinder
PNPontus Naucler
Pontus Naucler
AMAndreas Mårtensson
Andreas Mårtensson
TATobias Alfven
Tobias Alfven
Background: There is a need to better distinguish viral infections from antibiotic-requiring bacterial infections in children presenting with clinical community-acquired pneumonia (CAP) to assist health care workers in decision making and to improve the rational use of antibiotics. Objective: The overall aim of the Trial of Respiratory infections in children for ENhanced Diagnostics (TREND) study is to improve the differential diagnosis of bacterial and viral etiologies in children aged below 5 years with clinical CAP, by evaluating myxovirus resistance protein A (MxA) as a biomarker for viral CAP and by evaluating an existing (multianalyte point-of-care antigen detection test system [mariPOC respi] ArcDia International Oy Ltd.) and a potential future point-of-care test for respiratory pathogens. Methods: Children aged 1 to 59 months with clinical CAP as well as healthy, hospital-based, asymptomatic controls will be included at a pediatric emergency hospital in Stockholm, Sweden. Blood (analyzed for MxA and C-reactive protein) and nasopharyngeal samples (analyzed with real-time polymerase chain reaction as the gold standard and antigen-based mariPOC respi test as well as saved for future analyses of a novel recombinase polymerase amplification–based point-of-care test for respiratory pathogens) will be collected. A newly developed algorithm for the classification of CAP etiology will be used as the reference standard. Results: A pilot study was performed from June to August 2017. The enrollment of study subjects started in November 2017. Results are expected by the end of 2019. Conclusions: The findings from the TREND study can be an important step to improve the management of children with clinical CAP. International Registered Report Identifier (IRRID): DERR1-10.2196/12705

1 January 2025 in International Journal of Microbiology
Verified
Journal Article
Open access
AEAnnika Eklundh
Annika Eklundh
SRSamuel Arthur Rhedin
Samuel Arthur Rhedin
VPVille Peltola
Ville Peltola
MWMatti Waris
Matti Waris
PNPontus Naucler
Pontus Naucler
MRMalin Ryd Rinder
Malin Ryd Rinder
Background: Real‐time polymerase chain reaction (PCR), the gold standard for viral diagnostics in children, is a sensitive but resource‐intensive method. Viral antigen tests are cheaper and more rapid but have lower sensitivity. The clinical relevance of PCR positivity has been questioned because of its high sensitivity and detection in asymptomatic individuals. Thus, we hypothesized that antigen test positivity might be more indicative of active infection than PCR positivity. The aim of this study was to evaluate the antigen test mariPOC Respi test for the detection of 10 respiratory viruses versus PCR in relation to viral load, days of illness, and immunological viral response. Methods: Children 1–59 months old with lower respiratory infections were prospectively enrolled at the emergency department, Sachs′ Children and Youth Hospital, Stockholm, Sweden, between 2017 and 2019. Nasopharyngeal samples were collected from all cases ( n = 314). The sensitivity and specificity of the mariPOC Respi test were assessed in children with and without an immunological viral response (defined as a blood myxovirus resistance Protein A level > 430 μ g/L), using PCR as the reference standard. Results: The highest sensitivity for mariPOC Respi test was attained for respiratory syncytial virus (68%; 95% confidence interval: 63–73). Restricting the analysis to cases with a viral immunological response did not alter the results considerably. Conclusion: These findings do not support the idea that mariPOC Respi test positivity to a higher degree than PCR correlates with clinical relevance, as indicated by an immunological viral response. The role of antigen tests in current clinical practice requires further discussion, particularly in the post–pandemic era. Trial Registration: ClinicalTrials.gov identifier: NCT03233516

18 November 2018 in JMIR Preprints
Verified
Preprint
Open access
SRSamuel Arthur Rhedin
Samuel Arthur Rhedin
AEAnnika Eklundh
Annika Eklundh
MRMalin Ryd Rinder
Malin Ryd Rinder
PNPontus Naucler
Pontus Naucler
AMAndreas Mårtensson
Andreas Mårtensson
TATobias Alfven
Tobias Alfven
BACKGROUND There is a need to better distinguish viral infections from antibiotic-requiring bacterial infections in children presenting with clinical community-acquired pneumonia (CAP) to assist health care workers in decision making and to improve the rational use of antibiotics. OBJECTIVE The overall aim of the Trial of Respiratory infections in children for ENhanced Diagnostics (TREND) study is to improve the differential diagnosis of bacterial and viral etiologies in children aged below 5 years with clinical CAP, by evaluating myxovirus resistance protein A (MxA) as a biomarker for viral CAP and by evaluating an existing (multianalyte point-of-care antigen detection test system [mariPOC respi] ArcDia International Oy Ltd.) and a potential future point-of-care test for respiratory pathogens. METHODS Children aged 1 to 59 months with clinical CAP as well as healthy, hospital-based, asymptomatic controls will be included at a pediatric emergency hospital in Stockholm, Sweden. Blood (analyzed for MxA and C-reactive protein) and nasopharyngeal samples (analyzed with real-time polymerase chain reaction as the gold standard and antigen-based mariPOC respi test as well as saved for future analyses of a novel recombinase polymerase amplification–based point-of-care test for respiratory pathogens) will be collected. A newly developed algorithm for the classification of CAP etiology will be used as the reference standard. RESULTS A pilot study was performed from June to August 2017. The enrollment of study subjects started in November 2017. Results are expected by the end of 2019. CONCLUSIONS The findings from the TREND study can be an important step to improve the management of children with clinical CAP. INTERNATIONAL REGISTERED REPOR DERR1-10.2196/12705